Rapamycin vs Metformin

Rapamycin and metformin are the two most discussed longevity drugs in geroscience. They work through different but partially overlapping pathways, carry distinct risk profiles, and appeal to different users.

Here is the rigorous comparison that longevity researchers actually debate. Rapamycin: Suppressing Growth to Extend Life mTOR (mechanistic target of rapamycin) is the master growth-and-build regulator.

High mTOR activity drives the cell growth and protein synthesis needed for youth — but chronically elevated mTOR in aging promotes cellular senescence, impairs autophagy, and accelerates age-related pathology.

Rapamycin puts the brakes on mTORC1, triggering autophagy and mimicking many effects of caloric restriction at the cellular level. Metformin: Promoting Repair Over Growth AMPK is the cellular energy sensor — activated when energy is low (as in fasting or exercise).

Metformin activates AMPK, which shifts cell metabolism from anabolic (growth) to catabolic (repair) mode, reduces hepatic glucose output, improves insulin sensitivity, and inhibits mTOR indirectly. Its effects broadly mimic aspects of caloric restriction and exercise adaptation.

Choose Rapamycin If… ✓ You are a healthy individual without T2D who is pursuing longevity specifically and has physician oversight willing to prescribe off-label. ✓ You are persuaded by the ITP mouse lifespan data — the strongest mammalian longevity evidence for any single compound.

✓ You train heavily and are concerned about metformin blunting exercise adaptations — weekly rapamycin dosing may be less disruptive than daily AMPK activation. ✓ You follow the Bryan Johnson Protocol or are aligned with the biohacker community around mTOR inhibition.

Choose Metformin If… ✓ You have type 2 diabetes or prediabetes — metformin remains the first-line standard of care with decades of validated safety. ✓ You want the most evidence-based longevity drug in terms of human safety data — 60+ years and tens of millions of patients globally.

✓ You want to participate in or align with the TAME trial framework — the only FDA Breakthrough-designated aging clinical trial. ✓ Cost matters — metformin is $4–15/month versus $50–200 for rapamycin from compounding pharmacies.

Bryan Johnson — whose Blueprint protocol is probably the most rigorous in longevity history — takes both rapamycin and metformin. The rationale is pathway complementarity: rapamycin directly suppresses mTORC1, while metformin inhibits mTOR indirectly through AMPK and also provides glucose and insulin benefits that rapamycin does not.

Some preclinical evidence suggests additive or synergistic effects on longevity pathways when both are combined. However, rapamycin does have modest glucose-raising effects (it impairs insulin secretion via mTORC1 in beta cells), and metformin can partially counteract this — making the combination metabolically complementary.

The main practical concerns with stacking: rapamycin's immunosuppressive effect (even at low weekly doses, wound healing may be slightly impaired), metformin's GI burden, and the need for physician monitoring of both glucose and immune markers.

This combination is not a DIY protocol.

Choosing between Rapamycin and Metformin depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.

Head-to-head clinical trial data between Rapamycin and Metformin is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.

Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.